论文部分内容阅读
目的观察不同浓度氢氯噻嗪对高血压治疗的安全性。方法回顾性分析120例高血压患者的临床资料,随机分成3组:12.5mg组,25mg组,37.5mg组,3组三组间各项指标均无统计学差异。结果12.5mg组和25mg组血钠、血钾、尿酸和血糖无明显影响,不良反应少。37.5mg组血压下降较12.5mg组和25mg组显著。但37.5mg组可致血尿酸升高,且乏力症状明显。H氢氯噻嗪起始剂量l2.5mg是安全有效的,如效果不理想,加至25mg亦为安全剂量。如仍不理想可试与其他降压药物联用。如患者联用其他降压药无效或有顾忌,可试将氢氯噻嗪加量至37.5mg,但需监测患者生化指标。
Objective To observe the safety of different concentrations of hydrochlorothiazide in the treatment of hypertension. Methods The clinical data of 120 hypertensive patients were retrospectively analyzed and randomly divided into three groups: 12.5mg group, 25mg group and 37.5mg group. There was no significant difference among the three groups. Results There were no significant effects of serum sodium, serum potassium, uric acid and blood glucose in 12.5mg and 25mg groups with less adverse reactions. 37.5mg group decreased blood pressure 12.5mg group and 25mg group significantly. However, 37.5mg group can cause elevated serum uric acid, and fatigue symptoms. H hydrochlorothiazide initial dose of l2.5mg is safe and effective, such as the effect is not ideal, add to 25mg also safe dose. If still not ideal can try other antihypertensive drugs. If patients with other antihypertensive drugs ineffective or scruples, try hydrochlorothiazide dosage to 37.5mg, but the need to monitor biochemical indicators.